Recent Updates
Recently added Catalysts

CC-95266

Phase 1

Multiple Myeloma | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: Feb 9, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment130

FDA Designations

No designations recorded

Clinical trial landscape

CC-95266 · 1 trial · 1 indication

Phase 1 1
NCT04674813A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaMultiple Myeloma
COMPLETED130 Analytics
PHASE1COMPLETED
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
NCT04674813130
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with Adverse Events (AEs)
Up to 2 years after CC-95266 infusion
Number of participants with significant laboratory abnormalities
Up to 2 years after CC-95266 infusion
Number of participants with Dose Limiting Toxicities (DLTs)
Up to 2 years after CC-95266 infusion
Maximum Tolerated Dose (MTD)
Up to 2 years after CC-95266 infusion
Recommended Phase 2 Dose (RP2D)
Up to 2 years after CC-95266 infusion

Secondary Endpoints

Pharmacokinetics - Maximum plasma concentration of drug (Cmax)
Up to 2 years after CC-95266 infusion
Pharmacokinetics - Time to peak (maximum) serum concentration (tmax)
Up to 2 years after CC-95266 infusion
Pharmacokinetics - Area under the curve for days 1-29 after CC-95266 infusion (AUC1-29)
Up to 2 years after CC-95266 infusion
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Administration of CC-95266EXPERIMENTAL -

Interventions

NameTypeDescription
CC-95266DRUGSpecified dose on specified days
FludarabineDRUGSpecified dose on specified days
CyclophosphamideDRUGSpecified dose on specified days
BendamustineDRUGSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Age ≥ 18 years * Participant has a diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Participants must have confirmed progressive disease (as per IMWG criteria) on or within 12 months of completing treatment with the last anti-myeloma treatment regime...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 221 trials

Top 20 of 25 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV16PHASE3Pomalidomide, Dexamethasone, Venetoclax
Bristol-Myers Squibb CompanyBMY18PHASE3Iberdomide, Lenalidomide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3IGI, 10%
GSK plc Sponsored ADRGSK17PHASE3Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Johnson & JohnsonJNJ28PHASE3Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone
Regeneron Pharmaceuticals, Inc.REGN11PHASE3Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Pfizer Inc.PFE11PHASE3Elranatamab, Lenalidomide
Sanofi SA Sponsored ADRSNY17PHASE3Isatuximab, Dexamethasone, Pomalidomide, Montelukast, Paracetamol/ Acetaminophen
AstraZeneca PLCAZN5PHASE3AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib
Gilead Sciences, Inc.GILD3PHASE3Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib
Karyopharm Therapeutics, Inc.KPTI6PHASE3Selinexor, Elotuzumab, Pomalidomide, Dexamethasone
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
BioLineRX Ltd. Sponsored ADRBLRX1PHASE3BL-8040/kg, G-CSF
C4 Therapeutics, Inc.CCCC3PHASE2Cemsidomide, Dexamethasone
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Autolus Therapeutics Plc Sponsored ADRAUTL1PHASE2AUTO CAR T cell therapy
Incyte CorporationINCY2PHASE1Ruxolitinib, Lenalidomide, Methylprednisolone
Moderna, Inc.MRNA2PHASE1mRNA-2808
BeOne Medicines Ltd. Sponsored ADRONC1PHASE1Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Unlock Competitive Intelligence